Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CP-868,596

Known as: CP-868596 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Abstract 141 Background: The clinically active FLT3 inhibitor AC220 is vulnerable in vitro to resistance-conferring mutations at… Expand
Is this relevant?
2011
2011
10012 Background: 8-10% of gastrointestinal stromal tumors (GIST) have activating mutations of the platelet-derived growth factor… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Focal amplification and gene rearrangement of the… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: Platelet-derived growth factor receptor… Expand
Is this relevant?
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: 8-10% of gastrointestinal stromal tumors… Expand
Is this relevant?
2010
2010
Background:Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD… Expand
Is this relevant?
2008
2008
3549 Background: CP-868,596 (CP) is a specific inhibitor of the platelet-derived growth factor receptors (PDGFR) and axitinib (AG… Expand
Is this relevant?
2007
2007
3524 Background: CP-868,596 is an orally available, highly specific inhibitor of platelet-derived growth factor receptors (PDGFR… Expand
Is this relevant?